Plus Therapeutics, Inc.
PSTV
$0.25
-$0.01-2.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.21M | 5.26M | 5.32M | 5.21M | 5.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.21M | 5.26M | 5.32M | 5.21M | 5.82M |
| Cost of Revenue | 8.38M | 7.62M | 8.05M | 9.57M | 10.58M |
| Gross Profit | -3.17M | -2.37M | -2.73M | -4.37M | -4.76M |
| SG&A Expenses | 12.13M | 11.09M | 10.04M | 10.57M | 9.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.51M | 18.71M | 18.09M | 20.14M | 20.52M |
| Operating Income | -15.30M | -13.46M | -12.77M | -14.93M | -14.70M |
| Income Before Tax | -22.39M | -20.58M | -19.03M | -27.12M | -12.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.39 | -20.58 | -19.03 | -27.12 | -12.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.39M | -20.58M | -19.03M | -27.12M | -12.98M |
| EBIT | -15.30M | -13.46M | -12.77M | -14.93M | -14.70M |
| EBITDA | -14.85M | -12.81M | -12.00M | -14.07M | -13.82M |
| EPS Basic | -29.57 | -30.03 | -30.35 | -30.83 | -2.07 |
| Normalized Basic EPS | -23.87 | -24.15 | -24.35 | -24.70 | -1.29 |
| EPS Diluted | -29.61 | -30.06 | -30.39 | -31.09 | -2.33 |
| Normalized Diluted EPS | -23.92 | -24.20 | -24.41 | -24.59 | -1.18 |
| Average Basic Shares Outstanding | 293.96M | 164.14M | 64.56M | 22.68M | 26.54M |
| Average Diluted Shares Outstanding | 454.72M | 324.90M | 225.33M | 26.92M | 30.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |